Skip to content

Clinical Epidemiology and Characteristics Of Covid-19 Cases Occurred In A Lymphoma Setting In The First Epidemic Phase (LymphoCov1)

Épidémiologie Clinique et caractéristiques Des Cas de Covid-19 Survenus Dans un Contexte de Lymphome Lors de la première Phase épidémique

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04386512
Acronym
LymphoCov1
Enrollment
89
Registered
2020-05-13
Start date
2020-05-15
Completion date
2020-07-15
Last updated
2020-08-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID, Lymphoma

Keywords

covid, lymphoma, epidemiology

Brief summary

The main objective of this retrospective clinical epidemiology study is to describe the characteristics of Covid-19 cases requiring hospitalization in adult patients with lymphomas during the initial phase of the epidemic (from 01/03/20 to 30/04/20). The specific objectives are to estimate the frequency of severe forms of Covid-19 and those requiring intensive care hospitalisation, as well as the mortality related to the epidemic among the active file of patients followed for lymphoma at each study site, to investigate whether certain chemotherapy and/or immunotherapy treatments seem to be associated with severe forms or prolonged evolutions of Covid-19, to describe possible atypical clinical forms among the population of patients treated for lymphoma. Translated with www.DeepL.com/Translator (free version)

Detailed description

I Methods : * Multicentric retrospective observational epidemiological study based on the collection of data from patient records. * Selection of voluntary hospital sites in regions with excess mortality during the epidemic phase. * Systematic identification of Covid-19 cases from coding data (PMSI) from the medical information departments which will be compared with the numbers of patients followed for lymphoma in the haematology departments of each site during the 6 months preceding the epidemic, identified through the PMSI. * Establishment of an ad hoc CRF for cases only with collection of clinical data concerning lymphoma and Covid-19 and routine biological data: Cytopenia (and in particular depth of lymphopenia), hypogammaglobulinemia, inflammatory markers. * Estimated total number of sites: 10-15 and number of cases to be collected: 50-60. Translated with www.DeepL.com/Translator (free version)

Interventions

None listed

Sponsors

Versailles Hospital
Lead SponsorOTHER

Study design

Observational model
CASE_ONLY
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patients at least 18 years of age with lymphoma and a diagnosis of Covid-19 requiring hospitalization. * In order not to bias the data by excluding patients with adverse outcomes, we will also collect data from deceased patients.

Exclusion criteria

Patients who refused to participate \-

Design outcomes

Primary

MeasureTime frame
mortality2 months
transfer to ICU2 months

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026